Eisai plans to file for marketing authorization applications of lecanemab in Japan and EU by the end of Eisai’s FY2022, which ends March 31, 2023. “Today’s filing is an important milestone for people living with Alzheimer’s disease, demonstrating the resilience of the scient...
Eisai plans to file for marketing authorization applications of lecanemab in Japan and EU by the end of Eisai's FY2022, which ends March 31, 2023. "Today's filing is an important milestone for people living with...